Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.

BACKGROUND: In the Medical Research Council (MRC) COIN trial, the epidermal growth factor receptor (EGFR)-targeted antibody cetuximab was added to standard chemotherapy in first-line treatment of advanced colorectal cancer with the aim of assessing effect on overall survival. METHODS: In this random...

Full description

Bibliographic Details
Main Authors: Maughan, T, Adams, R, Smith, C, Meade, A, Seymour, M, Wilson, R, Idziaszczyk, S, Harris, R, Fisher, D, Kenny, S, Kay, E, Mitchell, J, Madi, A, Jasani, B, James, MD, Bridgewater, J, Kennedy, M, Claes, B, Lambrechts, D, Kaplan, R, Cheadle, J
Format: Journal article
Language:English
Published: 2011

Similar Items